Stable production capacity for PXB mice
First written in FY2016. 7 of 15 entries say "Advanced", first in FY2019-Q3. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Disclosed a decline in full-year production resultsAnnual report
「PXB mouse business 366,737 77.2」
Production in the PXB mouse business was ¥366.737 million in the current consolidated fiscal year, or 77.2% of the previous year. Although the business plan calls for annual production of more than 4,000 mice, full-year production was below the previous year. - FY2023AdvancedAnnual report
「Our group's order backlog had accumulated in the previous consolidated fiscal year because PXB mouse supply was temporarily disrupted, but in the current consolidated fiscal year PXB mouse production returned to normal operations and orders already received were processed smoothly.」
States that, following the supply disruption in the previous fiscal year, PXB mouse production returned to normal operations and orders already received were processed smoothly. - FY2023-Q3AdvancedAnnual report
「Although order intake was slightly below the level of the previous year, when several large projects were won, it exceeded plan, and the order backlog is being worked down smoothly as the production-process problems that occurred in the previous fiscal year have been resolved.」
States that the production-process problems that occurred in the previous fiscal year have been resolved and the order backlog is being worked down smoothly. - FY2022MaterialisedAnnual report
「For PXB mouse supply, production at overseas facilities fell below plan because yields remained unstable, while domestic facilities also experienced a temporary decline in production due to problems, resulting in delays in deliveries and contract testing.」
Unstable yields at overseas facilities and problems at domestic facilities caused production to fall below plan, and delays in deliveries and contract testing actually occurred. - FY2022-Q3Supply shortfall affects order intake activitiesAnnual report
「However, the temporary decline in PXB mouse production due to process problems at domestic production facilities and delays in production at overseas facilities caused the supply shortfall to become pronounced, and began to affect order intake activities.」
States that the supply shortfall caused by previously reported process problems at domestic facilities and production delays overseas has also begun to affect order intake activities. - FY2022-Q2Supply shortfall caused by production delays and process problemsAnnual report
「The supply shortfall became pronounced as PXB mouse production remained below the initial plan.」
Production was delayed at overseas production facilities after the capital investment was completed, while process problems also occurred at domestic production facilities. As a result, production fell below plan and the supply shortfall became pronounced. - FY2022-Q1AdvancedAnnual report
「Meanwhile, as shortages of mice have persisted due to increasing demand for PXB mice, our group has worked to stabilize production by increasing output, including at overseas production sites.」
In response to increasing demand for PXB mice and continued shortages, the company is working to stabilize production through an increased-production structure that includes overseas production sites. - FY2021AdvancedAnnual report
「Our group's order intake has been recovering since the second quarter, and demand for PXB mice is increasing. We are increasing PXB mouse production while working to secure capacity for contract testing, including through partner CROs.」
While increasing production in response to the recovery in demand and working to secure contract-testing capacity, another section states that a temporary mouse shortage occurred because demand became concentrated. - FY2021-Q3AdvancedAnnual report
「This was mainly attributable to the expansion of PXB mouse production facilities at an overseas subsidiary, which increased buildings and structures by ¥85.636 million and tools, fixtures and equipment by ¥70.324 million.」
In connection with stable PXB mouse production capacity, disclosed the expansion of production facilities at an overseas subsidiary together with the amount of the increase in assets. - FY2020AdvancedAnnual report
「Our group consistently produces more than 4,000 PXB mice annually.」
The explanation of annual production capacity increased from the previous figure of more than 3,500 mice to more than 4,000. - FY2019RestatedAnnual report
「By week 11 after transplantation, approximately 80% or more of the transplanted mice have an estimated replacement rate of 70% or more. We consistently produce more than 3,500 PXB mice annually.」
Restates the explanation of the PXB mouse replacement rate, production yield and annual production capacity of more than 3,500 mice. - FY2019-Q3AdvancedAnnual report
「This was mainly due to an increase of ¥26.613 million in tools, equipment and fixtures from capital investments for the production of PXB mice and PXB-cells, primarily at the subsidiary KMT Hepatech,Inc., and an increase of ¥11.789 million in buildings and structures from an extension to the head office building, partly offset by a ¥27.177 million decrease in goodwill due to the amortization of goodwill.」
Disclosed that KMT Hepatech,Inc. made capital investments for the production of PXB mice and PXB-cells, increasing tools, equipment and fixtures by ¥26.613 million. - FY2018RestatedAnnual report
「By week 11 after transplantation, approximately 80% or more of the transplanted mice have an estimated replacement rate of 70% or more. We consistently produce more than 3,500 PXB mice annually.」
Restates the previous explanation of the PXB mouse replacement rate, production yield and annual production capacity of more than 3,500 mice. - FY2017RestatedAnnual report
「By week 11 after transplantation, approximately 80% or more of the transplanted mice have an estimated replacement rate of 70% or more. We consistently produce more than 3,500 PXB mice annually.」
Restates the previously disclosed figures for production yield and annual production capacity. - FY2016First statedAnnual report
「By week 11 after transplantation, approximately 80% or more of the transplanted mice have an estimated replacement rate of 70% or more. We consistently produce more than 3,500 PXB mice annually.」
Shows a production yield of approximately 80% or more and annual production of more than 3,500 mice.